Drug Search Results
More Filters [+]

AR-42

Alternative Names: ar-42, ar42, ar 42
Latest Update: 2024-03-01
Latest Update Note: PubMed Publication

Product Description

AR-42 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01129193)

Mechanisms of Action: HDAC6 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Alison Walker
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AR-42

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Renal Cell Carcinoma|Sarcoma|Neurofibromatoses|Neurofibromatosis 2|Meningioma|Neuroma, Acoustic|Acute Myeloid Leukemia|Kidney Diseases|Neurilemmoma|Burkitt Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Extranodal NK-T-Cell Lymphoma|Mantle-Cell Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Large-Cell Immunoblastic Lymphoma|Diffuse Large B-Cell Lymphoma|Multiple Myeloma|T-Cell Cutaneous Lymphoma|Intraocular Lymphoma|Mycosis Fungoides|Plasmablastic Lymphoma|Lymphoproliferative Disorders|Prolymphocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin|Testicular Cancer|B-Cell Marginal Zone Lymphoma|Prolymphocytic T-Cell Leukemia|Follicular Lymphoma|Prolymphocytic B-Cell Leukemia|Waldenstrom Macroglobulinemia|Lymphomatoid Granulomatosis|Immunoblastic Lymphadenopathy|Large-Cell Anaplastic Lymphoma|T-Cell Peripheral Lymphoma|Leukemia, Plasma Cell|Sezary Syndrome|Adult T-Cell Leukemia-Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

OSU-15004

P1

Completed

Multiple Myeloma

2020-11-14

14-078H

P1

Terminated

Neurofibromatoses|Neuroma, Acoustic|Meningioma|Neurilemmoma|Neurofibromatosis 2

2017-05-30

OSU-09102

P1

Completed

T-Cell Cutaneous Lymphoma|Burkitt Lymphoma|Follicular Lymphoma|Large-Cell Immunoblastic Lymphoma|Diffuse Large B-Cell Lymphoma|Adult T-Cell Leukemia-Lymphoma|Mantle-Cell Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Prolymphocytic T-Cell Leukemia|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Extranodal NK-T-Cell Lymphoma|T-Cell Peripheral Lymphoma|Multiple Myeloma|Immunoblastic Lymphadenopathy|Large-Cell Anaplastic Lymphoma|Lymphoma, Non-Hodgkin|Leukemia, Plasma Cell|Waldenstrom Macroglobulinemia|Prolymphocytic B-Cell Leukemia|Lymphomatoid Granulomatosis|Prolymphocytic Leukemia|Sezary Syndrome|Intraocular Lymphoma|Plasmablastic Lymphoma|Lymphoproliferative Disorders|Mycosis Fungoides|Testicular Cancer|B-Cell Marginal Zone Lymphoma

2017-01-07

MCC-14-10774

P1

Terminated

Kidney Diseases|Sarcoma|Renal Cell Carcinoma

2016-11-24

Recent News Events